ACADIA Pharma Q3 Loss Widens - Quick Facts

(RTTNews) - ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company, reported a third-quarter net loss of $24.8 million or $0.25 per share, compared to a loss of $10.7 million or $0.12 per share, prior year.

On average, seven analysts polled by Thomson Reuters expected the company to report a loss per share of $0.22 for the quarter. Analysts' estimates typically exclude special items.

Collaborative revenue was to $15 thousand, compared to $240 thousand, last year. Analysts expected revenue of $160 thousand for the quarter. Research and development expenses increased to $17.0 million for the third quarter of 2014, from $7.3 million for the comparable quarter of 2013.

ACADIA announced the company plans to submit its NUPLAZIDNDA for Parkinson's disease psychosis in the first quarter of 2015. The company had previously planned to submit the NDA near the end of 2014. The company said the decision to move back the planned submission is based on additional time required to complete preparations needed to support the FDA review of NUPLAZID.